Integra LifeSciences IART Tissue Reconstruction — Intangible asset amortization

Other segment segments

Specialty Surgery

$0—

Similar metrics at other companies

PANWProduct — Total intangible assets amortization

$37M—

REZIProducts and Solutions — Intangible asset amortization

$6M0.0%

COLLSegment — Intangible asset amortization

$55.47M0.0%

ADEAIntangible Assets Amortization

$15.93M+13.1%

DHRBiotechnology — Intangible Amortization

$234M+9.9%

MNKDAll Other Segments — Intangible Amortization

$4.37M+340%

Other financials

Income statement

See full

Revenue$391.9M+2.4%

Gross profit$217.0M+11.6%

Operating income$11.5M+174%

Net income-$4.6M+81.7%

EPS (diluted)-$0.06+81.8%

Balance sheet

See full

Cash & equivalents$236.8M-1.0%

Total debt$2.0B+3.2%

Total equity$1.0B-31.6%

Total assets$3.6B-11.7%

Cash flow

See full

Operating cash flow$9.8M+187%

CapEx$14.8M-48.7%

Free cash flow-$5.0M+87.4%

Valuation

See full

Market cap$1.38B+53.4%

Enterprise value$3.12B+21.1%

P/S0.8×+0.3×

Profitability

See full

Gross margin51.9%-1.6pp

Operating margin-29.8%-30.3pp

Net margin-30.1%—

FCF margin3.8%-6.3pp

Returns & leverage

See full

Return on equity-38.6%—

Debt / equity1.9×+0.6×

Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's tissue reconstruction — intangible asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Integra LifeSciences's tissue reconstruction — intangible asset amortization?: Integra LifeSciences (IART) reported tissue reconstruction — intangible asset amortization of $0 in Q1 2026.
What does tissue reconstruction — intangible asset amortization mean?: This represents the periodic expense recognized for the systematic allocation of the cost of intangible assets, such as patents or acquired technology, within the Tissue Reconstruction segment. It reflects the non-cash cost of maintaining the segment's intellectual property portfolio.